Relapsed Acute Promyelocytic Leukemia Previously Treated with All-Trans Retinoic Acid: Clinical Experience with a New Synthetic Retinoid, Am-80

References

• Huang ME., Ye C., Chen SR., Chai JR., Lu J., Zhoa L., Gu LJ., Wang Z. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M.T, Ballerini R., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell R.P., Jr, Frankel S.R, Miller W.H, Scheinberg D.A, Itri L.M, Hittelman W.N, Vyas R., Andreeff M., Tafuri A., Jakubowski A., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Ohno R., Yoshida H., Fukutani H., Naoe T., Ohshima T., Kyo T., Endoh N., Fujimoto T., Kobayashi T., Hiraoka A., Mizoguchi H., Kodera Y., Suzuki H., Hirano M., Akiyama H., Aoki N., Shindo H., Yokomaru S., the Leukemia Study Group of the Ministry and Welfare. Multi-institutional study of all-trans retinoic acid as a differentiation tharapy of refractory acute promyelocytic leukemia. Luekaemia Study group of the Ministry of Health and Welfare. Leukemia 1993; 7: 1722–1727
   PubMed Web of Science ®Google Scholar
• Ohno R., Ohnishi K., Taktshita A., Tanomoto M., Murakami H., Kanamaru A., Asou N., Kobayashi T., Kuriyama K., Ohmoto E., Sakamaki H., Tsubaki K., Hiraoka A., Yamada O., Oh H., Furusawa S., Matsuda S., Naoe T. All-trans retinoic acid tharapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia(APL) in Japan. Leukemia 1994; 3: 64–69, 8 supplement
   Google Scholar
• Frankel S.R, Eardley A., Heller G., Berman E., Miller WH., Dmitrovsky E., Warrell R.P., Jr. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Annals of Internal Medicine 1994; 120: 278–286
   PubMed Web of Science ®Google Scholar
• Kanamaru A., Takemoto Y., Tanimoto M., Murakami H., Asou N., Kobayashi T., Kuriyama K., Ohmoto E., Sakamaki H., Tsubaki K., Hiraoka A., Yamada O., Oh H., Saito K., Matsuda S., Minato K., Ueda T., Ohno R., the Japan Adult Leukemia Study Group. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995; 85: 1202–1206
   PubMed Web of Science ®Google Scholar
• Asou N., Adachi K., Tamura J., Kanamaru A., Kageyama S., Hiraoka A., Omoto E., Sakamaki H., Tsubaki K., Saito K., Ohono R., Japan Adult Leukemia Study Group (JALSG). All-trans retinoic acid tharapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy, the Japan Adult Leukemia Study Group (JALSG). Cancer Chemotherapy and Pharmacology 1997; 40(supplement)30–35
   Web of Science ®Google Scholar
• Chen ZX., Xue YQ., Zhang R., Tao RF., Xia XM., Li C., Wang W., Zu WY., Yao XZ., Ling BJ. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Warrell R.P., Jr, de The' H., Wang Z.Y, Degos L. Acute promyelocytic leukemia. New England Journal of Medicine 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Warrel R.P., Jr, Maslak P., Eardley A., Heller G., Miller W.H., Jr, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience. Leukemia 1994; 2: 33, 8 supplement
   Google Scholar
• Yamada O., Hatake K., Tanimoto M., Ishiyama T., Ohno R., Shirakawa S., Horiuchi A., Tomonaga M., Ohta K. Co-operative study of all-trans retinoic acid as a differentiation induction therapy of acute promyelocytic leukemia. Gan To Kagakuryoho 1994; 21: 1981–1989
   PubMedGoogle Scholar
• Degos L., Dombret H., Chomienne C., Daniel M.T, Miclea JM., Chastang C., Castaigne S., Fenaux P. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643–2653
   PubMed Web of Science ®Google Scholar
• Dore BT., Momparler RL. Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. Leukemia Research 1996; 20: 761–769
   PubMed Web of Science ®Google Scholar
• Li YP., Said F., Gallagher RE. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-a. Blood 1994; 83: 3298–3302
   PubMed Web of Science ®Google Scholar
• Kizaki M., Matsushita H., Takayama N., Muto A., Ueno H., Awaya N., Kawai Y., Asou H., Kamada N., Ikeda Y. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood 1996; 88: 1824–1833
   PubMed Web of Science ®Google Scholar
• Robertson KA., Emami B., Collins SJ. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992; 80: 1885–1889
   PubMed Web of Science ®Google Scholar
• Muindi J., Frankel S.R, Miller W.H., Jr, Jakubowski A., Scheinberg D.A, Young C.W, Dmitrovsky E., War-Rell R.P., Jr. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Muindi J.R, Frankel S.R, Huselton C., DeGrazia R., Garland W.A, Young C.W, Warrell R.P., Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Caneer Research 1992; 52: 2138–2142
   PubMed Web of Science ®Google Scholar
• Usuki K., Endo M., Osawa M., Kitazume K., Iki S., Urabe A. Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia. International Journal of Hematology 1996; 63: 19–23
   PubMed Web of Science ®Google Scholar
• Agadir A., Cornic M., Lefebvre P., Goumel B., Jerome M., Degos L., Fenaux P., Chomienne C. All trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: Intracellular concentrations and biologic response relationship. Journal of Clinical Oncology 1995; 13: 2517–2523
   PubMed Web of Science ®Google Scholar
• Roberts A.B, Nichols M.D, Newton D.L, Sporn M.B. In vitro metabolism of retinoic acid in hamster intestine and liver. Journal of Biological Chemistry 1979; 254: 6296–6302
   PubMed Web of Science ®Google Scholar
• Roberts A.B, Lamb L.C, Sporn M.B. Metabolism of all-trans retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy-to 4-keto retinoic acid. Archives of Biochemistry and Biophysics 1980; 199: 374–383
   PubMed Web of Science ®Google Scholar
• Muindi JF., Young C.W. Lipid hydroperoxidases greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Research 1993; 53: 1226–1229
   PubMed Web of Science ®Google Scholar
• Kizaki M., Ueno H., Yamazoe Y., Shimada M., Takayama N., Muto A., Matsushita H., Nakajima H., Morikawa M., Koeffler HP., Ikeda Y. Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein. Blood 1996; 87: 725–733
   PubMed Web of Science ®Google Scholar
• Cornic M., Delva L., Guidez R., Balitrand N., Degos L., Chomienne C. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Research 1992; 52: 3329–3334
   PubMed Web of Science ®Google Scholar
• Cornic M., Delva L., Castaigne S., Lefebvre P., Balitrand N., Degos L., Chomienne C. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994; 8: 914–917
   PubMed Web of Science ®Google Scholar
• Adamson P.C, Boylan JR., Balis F.M, Murphy R.F, God-Win K.A., Gudas L.J, Poplack D.G. Time Course of Induction of Metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Research 1993; 53: 472–476
   PubMed Web of Science ®Google Scholar
• Delva L., Cornic M., Balitrand N., Guidez E., Miclea JM., Delmer A., Teillet F., Fanaux R., Castaigne S., Degos L., Chomienne C., et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175–2181
   PubMed Web of Science ®Google Scholar
• Hirschel-Scholz S., Siegenthaler G., Saurat JH. Ligand-specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP). European Journal of Clinical investigation 1989; 19: 220–227
   PubMed Web of Science ®Google Scholar
• Hirschel-Scholz S., Siegenthaler G., Saurat JH. Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoic acid binding protein (CRABP). British journal of dermatology 1989; 120: 639–644
   PubMed Web of Science ®Google Scholar
• Miller W.H., Jr, Jakubowski A., Tong W.P., Miller V.A., Rigas J.R., Benedetti F., Gill G.M., Truglia J.A., Ulm E., Shirley M., Warrell R.P. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995; 85: 3021–3027
   PubMed Web of Science ®Google Scholar
• Rigas J.R, Francis P.A, Muindi JR., Kris M.G, Huselton C., DeGrazia F., Orazem J.P, Young C.W., War-Rell R.P., Jr. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. Journal of the National Cancer Institute 1993; 85: 1921–1926
   PubMed Web of Science ®Google Scholar
• Schwartz E.L, Hallam S., Gallagher R.E, Wiernik P.H. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochemical Pharmacology 1995; 50: 23–928
   Web of Science ®Google Scholar
• Estey E., Thall P.F, Mehta K., Rosenblum M., Brewer T., Jr, Simmons V., Cabanillas F., Kurzrock R., Lopez-Berest-Ein G. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 1996; 87: 3650–3654
   PubMed Web of Science ®Google Scholar
• Hashimoto Y., Shudo K. Retinoids and their nuclear receptors. Cell biology reviews 1991; 25: 209–230
   Google Scholar
• Hashimoto Y. Retinobenzoic acids and nuclear retinoic acid receptors. Cell structure and function 1991; 16: 113–123
   PubMed Web of Science ®Google Scholar
• Zelent A., Krust A., Petkovich M., Kastner R., Cham-Bon P. Cloning of murine alpha and beta retinoic acid receptors and a novel receptor gamma predominantly expressed in skin. Nature 1989; 339: 714–717
   PubMed Web of Science ®Google Scholar
• Kagechika H., Kawachi E., Hashimoto Y., Himi T., Shudo K. Retinobenzoic acids. 1.Structure-activity relationships of aromatic amides with retinoidal activity. Journal of Medical Chemistry 1988; 31: 2182–2192
   PubMed Web of Science ®Google Scholar
• Hashimoto Y., Kagechika H., Kawachi E., Fukasawa H., Saito G., Shudo K. Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB-4. Journal of Cancer Research and Clinical Oncology 1995; 121: 696–698
   PubMed Web of Science ®Google Scholar
• Okamura T., Masuda M., Arai Y., Mizoguchi H. Am-80 induced differentiation of HL60 myeloid leukemic cells. International Journal of Hematology 1995; 61, Supplement 159
   PubMedGoogle Scholar
• Tobita T., Takeshita A., Kitamura K., Ohnishi K., Yanagi AM., Hiraoka A., Karasuno T., Takeuchi M., Miyawaki S., Ueda R., Naoe J., Ohno R. Treatment with a new synthetic retinoid, Am-80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retin-oic acid. Blood 1997; 90: 967–973
   PubMed Web of Science ®Google Scholar
• Takeshita A., Shibata Y., Shinjo K., Yanagi M., Tobita T., Ohnishi K., Miyawaki S., Shudo K., Ohono R. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. Annals of Internal Medicine 1996; 124: 893–896
   PubMed Web of Science ®Google Scholar
• Takeuchi M., Yano T., Omoto E., Takahashi K., Kibata M., Shudo K., Ueda R., Ohono R., Harada M. Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. British Journal of Haematology 1997; 97: 137–140
   PubMed Web of Science ®Google Scholar
• Chomienne C., Ballerini P., BaJitrand N., Daniel M.T, Fenaux P., Castaigne S., Degos L. All-trans retinoic acid in acute promyelocytic leukemias. II In vitro studies; Structure-function relationship. Blood 1990; 76: 1710–1717
   PubMed Web of Science ®Google Scholar
• Dyck JA., Maul G.G, Miller W.H., Jr, Chen J.D, Kaki-Zuka A., Evans R.M. A novel macromolecular structure is a target for the promyelocytic-retinoic acid receptor oncoprotein. Cell 1994; 76: 333–343
   PubMed Web of Science ®Google Scholar
• Dyck J.A, Warrell R.P., Jr, Evans R.M, Miller W.H., Jr. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RARa protein. Blood 1995; 86: 862–867
   PubMed Web of Science ®Google Scholar
• Naoe T., Yoshida H., Kitamura K., Chino M., Osumi K., Ohno R. Delayed or insufficient restoration of PML and PML-RARa subcellular localization after exposure in vitro to retinoic acids in all-trans retinoic acid-resistant APL cells. Leukemia 1995; 9: 1610–1611
   PubMed Web of Science ®Google Scholar
• Weis K., Ramboaud S., Lavau C., Jansen J., Carvalho T., Carmo-Fonseca M., Lamond A., Dejean A. Retinoic acid regulates aberrant nuclear localization of PML-RAR a in acute promyelocytic leukemia cells. Cell 1994; 76: 345–356
   PubMed Web of Science ®Google Scholar
• Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., Ohno R., Naoe T. Accelerated degradation of PML-retinoic acid receptor α (PML-RARA) oncoprotein by all-trans retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Research 1996; 56: 2945–2948
   PubMed Web of Science ®Google Scholar
• Chen G.Q, Zhu J., Shi X.G, Ni J.H, Zhong H.J, Si G.Y, Jin X.L, Tang W., Li X.S, Xong S.M, Shen Z.X, Sun G.L, Ma J., Zhang P., Zhang T.D, Gazin C., Naoe J., Chen SJ., Wang Z.Y, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Kitamura K., Yoshida H., Ohno R., Naoe T. Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. International Journal of Hematology 1997; 65: 179–185
   PubMed Web of Science ®Google Scholar
• Shen ZX., Chen GQ., Li XS., Ni JH., Tang W., Fang ZW., Chen SJ., Wang ZY., Chen Z. Use of arsenic trioxide (As2O3) in the treament of APL: II Remission induction in relapsed patients and pharmacokinetics. Blood 1996; 88, (abstr, suppl), 1996.
   Web of Science ®Google Scholar